KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash from Operations (2018 - 2025)

Vir Biotechnology's Cash from Operations history spans 8 years, with the latest figure at 25876000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 70.47% year-over-year to 25876000.0; the TTM value through Dec 2025 reached 391781000.0, up 12.23%, while the annual FY2025 figure was 391781000.0, 12.23% up from the prior year.
  • Cash from Operations for Q4 2025 was 25876000.0 at Vir Biotechnology, up from 167570000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 960136000.0 in Q2 2022 and bottomed at 389247000.0 in Q2 2023.
  • The 5-year median for Cash from Operations is 88582000.0 (2021), against an average of 62700.0.
  • The largest annual shift saw Cash from Operations surged 1416.46% in 2021 before it tumbled 407.26% in 2023.
  • A 5-year view of Cash from Operations shows it stood at 7695000.0 in 2021, then skyrocketed by 356.48% to 35126000.0 in 2022, then crashed by 407.26% to 107927000.0 in 2023, then increased by 18.8% to 87635000.0 in 2024, then soared by 70.47% to 25876000.0 in 2025.
  • Per Business Quant, the three most recent readings for VIR's Cash from Operations are 25876000.0 (Q4 2025), 167570000.0 (Q3 2025), and 120219000.0 (Q2 2025).